Global First-in-Class AT2R Antagonist TRD205 Phase II Trial
05 May 2025 //
PR NEWSWIRE
Akeso’s Anniko enters crowded US PD-1 market
25 Apr 2025 //
FIERCE PHARMA
CU Medicine, CTTQ Collaborate On Pharma Innovations In Hong Kong
10 Dec 2024 //
BIOSPECTRUM
Sino Biopharmaceutical to divest 67% stake in unit CP Qingdao for $253 mln
06 Feb 2024 //
REUTERS
Sino received IND approval from the NMPA to initiate trial with lanifibranor
25 May 2023 //
GLOBENEWSWIRE